Elizabeth Head on Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.

COMMENT the design of these studies, and there are many exciting avenues being explored (e.g., comment by Dr.

Roy Weller on Trial Troika—Immunotherapy Interrupted, Lipitor Lags, Dimebon Delivers

COMMENT commented on the possible mechanism of the vasculitis and raised the problem of how Aβ is deposited in

Bart De Strooper on Keystone: γ Slowly Relinquishes Its Secrets

COMMENT We enjoy reading about the enthusiasm raised by the recent findings by the Iwatsubo group with regard to cysteine scanning mutagenesis of PS1, which was presented at the Keystone meeting. We actually presented at the same Keystone meeting, 24-29 March, Co

Dave Morgan on AD Immunotherapy: Toward Prevention, DNA-based Vaccines?

COMMENT I have a couple of quick points to make. First, Michael Agadjanyan is a brilliant immunologist. He and Dave Cribbs have been leaders in the development of safer and effective active immunization protocols against Aβ, both in this manuscript and others. Se

Valerie Cullen on Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders.

COMMENT This paper adds momentum to the growing concept that GBA mutations play a role in the susceptibility to the Lewy body disorders PD and DLB. Importantly, a large number of patients and controls were studied, although only the two most common GBA mutations

Kevin Barnham on Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease.

COMMENT inaccuracies in Boris Schmidt’s comment. First, clioquinol did not fail as an AD therapy because of “metal

Corinne Augelli-Szafran on Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease.

COMMENT Having read this interesting paper, it seems to me that at this point, these types of molecules are not druggable. Looking at the structures, I would ask whether these compounds are toxic and insoluble. Follow-up work could specifically address potential

Gordon Wilcock on Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.

COMMENT We would like to thank Dr. Doody for her balanced commentary on our paper about the Phase 2 trial of Tarenflurbil. It was a successful study at this level in that it prepared the way for the Phase 3 studies that have followed. Number of Patients COMPLETED

Boris Schmidt on Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease.

COMMENT This is novel and interesting work; however, it raises questions concerning approved AD targets and recent progress in the understanding of DNA repair. Clioquinol, which was advanced for AD therapy by some of the authors, failed for metal chelation-associ

Claudia Bagni on Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.

COMMENT Bart De Strooper and his collaborators have characterized a microRNA cluster (miR29a/b-1) that is significantly and specifically downregulated in AD patients. miRNAs are extremely important regulators of gene expression that modulate both translation effi

Kevin Barnham on Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease.

COMMENT We'd like to respond to Austin Yang’s comment. The purpose of the NMR and mass spectroscopy

Terrence Town on Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.

COMMENT This interesting paper by Movsesyan and coworkers describes a novel DNA-based Aβ vaccine that relies on amino acids 1-11 of the peptide in combination with the synthetic T cell peptide, PADRE, and the Th2-promoting chemokine CCL22. The authors have nicely

William Klunk on Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.

COMMENT of when we need to intervene in AD remains relevant and important. The comments raised by Michael

Roger N. Rosenberg on Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.

COMMENT This study is an important advance showing that gene vaccines delivered by gene gun may hold promise for future use in the fight against Alzheimer disease. In 2003, Ghochikyan et al. (1) constructed a DNA minigene with Aβ fused to mouse interleukin-4 (pAβ

Giuseppina Tesco on Mice, Flies Further Implicate Retromer in AD Pathogenesis

COMMENT Small and colleagues (1) had previously shown that VPS26 and VPS35 are decreased in AD brains and that siRNA-mediated depletion of VPS26 and VPS35 produces an increase in Aβ levels in vitro. In this interesting paper, Muhammad and colleagues report that V